• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA: Medical device industry tells agency to take a time out on user fee reauthorization

FDA: Medical device industry tells agency to take a time out on user fee reauthorization

June 20, 2011 By MassDevice staff

FDA

The medical device industry is asking the FDA to take a couple more years to meet goals it says the watchdog agency has failed to meet before it agrees on reauthorizing user fees for another go-around.

In the Medical Device User Fee Reauthorization or MDUFMA III negotiation meeting, which was held early in June, a group representing the medical device industry said the agency has “not yet achieved” some of the qualitative and quantitative goals set when the user fee program was reauthorized in 2007.

The minutes of the negotiation meeting, which included representatives from FDA, CDRH, as well as AdvaMed, MDMA and MITA were released today on the FDA web site.

Industry’s well-documented gripes included increased review times for medical devices across the board and inconsistent spending of user fee collections.

“Industry characterized FDA’s performance by asserting a lack of focused and consistent training on core competencies and training to enhance scientific expertise, a lack of analysis of training effectiveness, and not holding vendor days in 2010 and holding limited reviewer site visits,” according to minutes of the meeting.

In addition, industry reps said that while it supported the goals and objectives of the user fee program, the current climate was not conducive to a new agreement on the user fee program and offered a compromise of extending the current program.

“Industry expressed concerns about developing meaningful goals and agreeing to associated resources for a five year program. Industry noted its intent was not to abort the program, but rather, to wait for FDA to resolve these policy issues and to allow FDA additional time to achieve MDUFA II commitments.”

Under the proposed compromise, industry would continue to pay user fees at current levels, allowing for a 4 percent inflationary increase each year.

“FDA asked if Industry considered the funding shortfalls this would create for the program, given that this would represent a decrease in MDUFA user fee spending. Industry acknowledged that there would be a decrease in MDUFA user fee spending,” according to the meeting notes.

FDA negotiators said they needed more time to consider the proposal and tabled its presentation of a commitment letter for the five-year reauthorization plan until a later meeting.

The current user fee act is set to expire in 2012. The agency first won the authority to collect user fees under the 2002 Medical Device User Fee and Modernization Act. The program was reauthorized in 2007 under MDUFMA II. The user fees were supposed to make up for the FDA’s resource shortfall to help it review device applications more quickly and, ultimately, speed devices to market. In return for receiving industry funding, the FDA was tasked with meeting performance goals under MDUFMA, which set benchmarks for measuring improvements in the agency’s review times.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: 510(k) reforms, AdvaMed

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy